Market Overview

2 Possible Scenarios For Opthotech

2 Possible Scenarios For Opthotech
Related OPHT
In Honor Of Friday The 13th, Here Are Some Of The Unluckiest Trades Of 2016
Regeneron Eyes A Comeback In 2017
Related REGN
Top 10 S&P Stocks Of The Obama Presidency
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
Implications Of The Latest Smash In Bristol-Myers Squibb Stock (Seeking Alpha)

Kyle Dennis, co-founder of, recently joined PreMarket Prep to share his thoughts on Opthotech Corp (NASDAQ: OPHT). According to Dennis, Opthotech will either be a huge hit or miss for traders within the next month.

The Answer Will Come Soon

Dennis pointed out that Opthotech shares have been driven down from above $60 to around $32 following disappointing data from competitor Regeneron Pharmaceuticals Inc (NASDAQ: REGN).

“Regeneron has some negative data with a drug that’s similar to what OPHT has,” Dennis explained.

“Traders and investors are speculating that OPHT is going to have bad data, but I don’t necessarily know that’s the case. I tend to be more positive on the name.”

Opthotech’s data is due out in December, and Dennis believes Opthotech stock will be on the move one way or another.

“It’s either going to be, in my opinion, a $15 stock or it’s going to be close to $100. It’s really important glaucoma data. If it is positive, it’s going to be transformative for this company,” he said.

He concluded the discussion by warning traders to expect extreme volatility in the stock following the release of the data. However, for traders that can stomach the risk, Opthotech is positioned for some major near-term upside.

At last check, Opthotech was trading down 9.46 percent at $30.81.

Latest Ratings for OPHT

Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Dec 2016Goldman SachsUpgradesSellNeutral
Dec 2016Gabelli & Co.DowngradesBuyHold

View More Analyst Ratings for OPHT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Analyst Ratings Movers Media Trading Ideas Interview Best of Benzinga


Related Articles (REGN + OPHT)

View Comments and Join the Discussion!